Hims & Hers has been removed from that program. "Novo Nordisk is firm on our position and protecting patients living with obesity," said Dave Moore, Novo Nordisk's executive vice president of US ...

Semaglutide — the active ingredient in Ozempic®, Wegovy®, and Rybelsus® — can reduce your appetite and curb food cravings to promote weight loss. But if you’re still hungry on semaglutide ...

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full trial results for humans are expected later in 2025. Results from the Phase ...

You can take semaglutide for weight loss indefinitely. There’s no set cut-off time, as the drug was originally designed as a diabetes medication and intended for long-term use.

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. Following a review ...

Nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss, is a “very rare” side effect of treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study found, and what a doctor has to say about it.

Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 ...

This week's topic is semaglutide, the popular weight loss drug that has taking the world by storm in recent years. Join our hosts and guest patient Jennifer Weber as they go over the history of ...

Semaglutide and similar GLP-1 drugs have proven to be highly effective obesity and type 2 diabetes treatments. But like every drug, they have their possible trade-offs, including muscle loss.

Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their risk of developing neovascular age-related macular degeneration (nAMD ...